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ABSTRACT Bone morphogenetic proteins (BMPs) are re-
sponsible for bone formation during embryogenesis and bone
regeneration and remodeling. The osteoinductive action of
BMPs, especially BMP-2 and BMP-7, has led to their use in a
range of insurmountable treatments where intervention is re-
quired for effective bone regeneration. Introduction of BMP
products to the market, however, was not without reports of
multiple complications and side effects. Aiming for optimization
of the therapeutic efficacy and safety, efforts have been focused
on improving the delivery of BMPs to lower the administered
dose, localize the protein, and prolong its retention time at the
site of action. A major challenge with these efforts is that the
protein stability should be maintained. With this review we at-
tempt to shed light on how the stability of BMPs can be affected
in the formulation and delivery processes. We first provide a
short overview of the current standing of the complications ex-
perienced with BMP products. We then discuss the different
delivery parameters studied in association with BMPs, and their
influence on the efficacy and safety of BMP treatments. In par-
ticular, the literature addressing the stability of BMPs and their
possible interactions with components of the delivery system as
well as their sensitivity to conditions of the formulation process is
reviewed. In summary, recent developments in the fields of bio-
engineering and biopharmaceuticals suggest that a good under-
standing of the relationship between the formulation/delivery
conditions and the stability of growth factors such as BMPs is a
prerequisite for a safe and effective treatment.
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TGF-β Transforming growth factor β
USE OF BONE MORPHOGENETIC PROTEINS
FOR BONE REGENERATION
Introduction
Bone tissue has a unique self-remodeling and regeneration
capability. Therefore, the standard treatment for bone defects
such as fractures is composed of reduction and fixation of the
fracture, acting as secondary aid to the self-healing process. In
some instances (e.g., nonunion fractures of critical size defects,
spinal fusions, open tibial fractures, and bone augmentation in
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dental implantology), the bone self-regeneration capacity is
not sufficient and a more profoundmedical/surgical interven-
tion to induce the formation of new bone is required. For such
cases the use of autologous bone grafting, specifically iliac crest
bone grafting (ICBG), has been considered as the Bgold
standard^ treatment, as it provides a structural lattice that al-
lows for cell migration, proliferation and tissue regeneration by
employment of growth factors and osteoprogenitor cells [1].
This treatment, however, comes with multiple disadvantages,
such as donor site morbidity represented in high postoperative
pain, extended operating time with increased intra-operative
blood loss, risk of infection and injury to nerves and blood
vessels, possible postoperative gait disturbances, and limited
availability of the graft especially in elderly patients [2, 3].
These limitations have driven the research towards tissue engi-
neering approaches using bioactive molecules and materials.
Nature of BMPs and their Applications
Bone morphogenetic proteins (BMPs) are naturally occurring
molecules that were first identified by Urist in 1965 as proteins
present in demineralized bone matrix that are capable of
osteoinduction in ectopic sites in rats [4, 5]. Apart from
BMP-1 (a metalloprotease), BMPs constitute a sub-class of
the transforming growth factor β (TGF-β) superfamily [6].
To this date, around 20 BM Ps have been discovered; how-
ever, not all of them are in fact osteogenic molecules [7, 8].
BMP-2 and BMP-7 are, arguably, the strongest inducers of
bone and cartilage formation.While BMP-4, BMP-5, BMP-6,
BMP-8, BMP-9, and BMP-10 contribute to bone formation
as well, BMP-3 and BMP-13 act as BMP inhibitors [9, 10].
The other BMP members are involved in developmental ac-
tivities other than osteogenesis [8, 11].
A big share of the research efforts has been focused on the
development of BMP-2 and BMP-7 drug products. After ini-
tial work using bovine BMPs, in the late 1980s, the molecular
cloning of the human BMP genes was successfully achieved
[12]. Since then, several BMP family members have been
separated and in addition human recombinant BMP-2 and
BMP-7 (further referred to as rhBMP-2 and rhBMP-7, re-
spectively) were produced and purified for therapeutic appli-
cations [13, 14]. Evidence of their ability to induce bone in
spinal fusions and nonunions in animal models led to their
investigation in human clinical trials and the introduction of
products to the biopharmaceutical market as a therapeutic
replacement for ICBG.
Structure and Properties of BMPs
A common denominator among BMPs is the presence of a
cysteine knot involving 6 cysteine residues as well as a heparin-
binding site [15]. These sites essentially interact with the en-
dogenous macromolecules heparin/heparin sulfate present on
cell surfaces and the extracellular matrix, resulting in the reg-
ulation of the bone formation process [16, 17]. Like all the
other BMPs, BMP-2 and BMP-7 exist as homodimers where
two BMP molecules are held together by a disulfide bridge
through a 7th cysteine residue in their structure [18, 19]. This
dimeric nature of BMPs is a necessary requirement for their
biological activity, as the breakage of the disulfide bridges
holding the molecules together renders the proteins inactive.
Human BMP-2 contains 114 amino acid residues and has
a molecular weight of ~32 kDa [20]. BMP-7 consists of 139
amino acids and has a molecular weight of ~36 kDa [21, 22].
The molecular weight in both cases represents the dimeric
existence of the molecules. All BMPs are basic proteins where
they have their isoelectric points (pI) between 7.7 and 9, with
BMP-2 and BMP-7 having very similar pIs at 8.2 [23] and 8.1
[21], respectively. Furthermore, they have abundant hydro-
phobic patches on their surface, represented in white in Fig. 1.
Therefore, they show limited solubility at physiological pH, a
property that is thought to be relevant to their pharmacolog-
ical activity [18]. Rapid clearance is another feature of BMPs.
For instance, when administered in buffer only, BMP-2 has a
half-life time of ~7 min in non-human primates [24, 25].
An important parameter to consider when constructing a
BMP product is that BMPs are pleiotropic proteins, meaning
that they influence at least one or more molecular pathways
beside their role in bone regeneration [26, 27]. Therefore,
their diffusion to nearby tissues can result in unwanted ectopic
bone formation, native bone resorption, and/or swelling of
soft tissue [28]. These facts emphasize the importance of the
Fig. 1 Surface charge density of rhBMP-2. Red and blue colors indicate
negative and positive electrostatic potential, respectively. White color repre-
sents hydrophobic regions [18].
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incorporation of BMPs into delivery systems with program-
mable spatiotemporal release that would allow the presence of
physiological doses of BMP only in the confined space which is
limited to the defect region.
Current BMP Products and Overview of Historical
Events
Presently, there is one rhBMP-2 product on the market which
is marketed as the INFUSE® Bone Graft Kit (Medtronic) in
the US and as InductOS® Kit (Wyeth) in Europe. It is a
lyophilized product containing rhBMP-2 at a concentration
of 1.5 mg/ml after reconstitution, along with an absorbable
collagen sponge (ACS) as a carrier for the protein. The prod-
uct is commercially available at the total doses of 6 and 12mg.
Since the collagen sponge does not provide adequate mechan-
ical support, the product needs to be combined with a sup-
portive structure such as the LT-CAGE®, also produced by
Medtronic. It is a titanium tapered cage that is implanted
during the surgery as an interbody fusion device for spinal
fusion procedures. The product has been introduced as an
alternative treatment for bone grafting for multiple clinical
conditions including spinal fusions, internal fixation of frac-
tures, treatment of bone defects and reconstruction of maxil-
lofacial conditions [29].
During the late 1990s and early 2000s, clinical trials were
performed to compare the rhBMP-2/ACS treatment against
the standard ICBG in anterior lumbar interbody fusion (ALIF)
procedures. Results of these trials showed higher fusion rates for
the rhBMP-2/ACS treated groups, and either similar or im-
proved back and leg pain indices [30–32]. The impressive re-
ported outcomes of the clinical studies resulted in the US Food
and Drug Administration (FDA) approval in 2002 of the
INFUSE® Bone Graft for spine fusion procedures employing
the ALIF technique. Additional FDA approvals followed in
2004 for the use of rhBMP-2 to treat acute and open fractures
of the tibial shaft, and in 2007 for oral maxillofacial applications
[29]. The FDA approval, in turn, led to amarked increase in the
use of rhBMP-2 in spinal fusion procedures from 0.69% of all
fusions in the US in 2002 to 24.89% in 2006 [33, 34].
With this increased use of rhBMP-2 in the different ortho-
pedic procedures, reports started to emerge regarding a series
of safety concerns and possible side effects that were not pub-
lished in the early clinical trials [35]. Ectopic/heterotopic
bone formation [36, 37], dysphagia in cervical spinal fusions
[38], vertebral bone resorption (osteolysis) [33, 39], postoper-
ative radiculitis [40, 41], postoperative nerve root compres-
sion [42, 43], graft subsidence, and cage migration [33, 44]
were among the frequently reported side effects. Mixed ac-
counts were reported of the effect of rhBMP-2 on the inci-
dence of retrograde ejaculation [45–48], and on its carcino-
genic effects [49–54].
An extensive review by Carragee et al. [48] reassessed the
efficacy and safety of the rhBMP-2 treatments published in 13
different clinical studies [30–32, 55–63]. The authors of the
review stated that the thirteen clinical trial publications had
consistently exaggerated the morbidity of the ICBG harvest-
ing procedure and at the same time underestimated the side
effects associated with the use of rhBMP-2, leading to false, or
at least inflated, estimations of the reported rhBMP-2 safety
and efficacy when compared with ICBG. After a revised as-
sessment of the side effects associated with the use of rhBMP-
2, which was reported to have Bperfect^ safety in the original
studies, the authors concluded that the true risk to the patients
is 10 to 50 times higher than that originally reported. For
further investigation of such serious findings, the Yale
University Open Data Access project team conducted a
meta-analysis of individual-participant data [64]. The re-
analyzed results considered the body of evidence strong
enough for the initially reported effectiveness of the rhBMP-
2 treatment but echoed the concerns related to the safety of
the rhBMP-2.
While much of the effort has been focused on rhBMP-2
development and assessment, BMP-7 also had a share of re-
search aiming at its introduction as a commercial product to
the biopharmaceutical market. The results of the first clinical
trial for rhBMP-7 in cases of tibial nonunions showed no signif-
icant difference between the rhBMP-7 treated group and the
ICBG treated group in terms of safety and efficacy; moreover,
they failed to prove superiority of the rhBMP-7 treatment over
the autogenous bone graft [65]. In 2001 and following this trial,
rhBMP-7 received a limited FDA approval in the US under a
Humanitarian Device Exemption for treatment of recalcitrant
tibial nonunions, and was subsequently introduced to the mar-
ket as OP-1 by Stryker Corporation in theUS and asOsigraft in
Europe. The OP-1 product is a putty containing 3.5 mg of
rhBMP-7, 1 g of type I bovine collagen matrix, and 230 mg of
the putty additive carboxymethylcellulose sodium (CMC) to be
reconstituted using sterile saline [66, 67].
Consecutive trials studied the use of OP-1 in patients suf-
fering from grade I or II spondylolisthesis. Whether OP-1 was
administered as an adjunct to or as a replacement for ICBG, it
was found to have similar results as the use of the autograft
alone in terms of bone bridging and showed no significant side
effects. Again, no statistically significant differences could be
established between the two treatments [67–69]. A large-
prospective-randomized-controlled-multicenter clinical trial
was started in an attempt to obtain an FDA Premarket
Approval (PMA), which allows for unlimited product usage
as long as it meets the approved use [70]. The trial aimed to
demonstrate non-inferiority of OP-1 against ICBG in treat-
ment of patients with spondylolisthesis. However, it did not
succeed in showing that OP-1 treatment is truly non-inferior
to ICBG. As a consequence, inMarch 2009, an FDA advisory
committee voted against the PMA request for OP-1. In 2010,
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Stryker Biotech sold the OP-1 assets to Olympus Biotech
Corp., which later in 2014 discontinued the sale of its prod-
ucts, including OP-1, in the US. Therefore, there are current-
ly no rhBMP-7 products on the market.
Dosing of BMPs
It has been suggested that the high doses of administered
BMPs are one of the main reasons behind the reported ad-
verse events accompanying their use in bone repair proce-
dures [44]. In all the previously discussed clinical trials and
all surgical treatments involving INFUSE® bone graft kit,
rhBMP-2 has been delivered at a supraphysiological concen-
tration [24, 44, 71–75]. Typically, the exogenous therapeutic
rhBMP-2 is administered at a dose in the milligram range,
which exceeds one million times the physiological protein
amount, produced in nanograms under normal bone repair
conditions [72]. The supraphysiological BMP-2 doses admin-
istered locally during the surgical procedure in clinical studies
have been connected with complications, such as generalized
hematomas in soft tissue [76], exaggerated inflammatory re-
sponse in proximal humeral fractures [77], unicameral bone
cysts [78], and infections in open tibial fractures [73, 79].
Furthermore, in an attempt to introduce a new rhBMP-2
product to the market, an Investigational Device Exemption
study was conducted using a high dose (40 mg) rhBMP-2 prod-
uct (called AMPLIFY, by Medtronic) on patients with single-
level degenerative lumbar disease [80]. After the two-year follow
up of the trial, the outcomes reported the incidence of eight
cancer cases in the patients treated with AMPLIFY as opposed
to two cancer cases in the control group receiving ICBG treat-
ment [58, 71]. In 2013, the FDA denied AMPLIFY a pre-
marketing approval following the occurrence of additional can-
cers in the AMPLIFY treated group [71]. It is noteworthy that
INFUSE uses 6 and 12 mg doses and the product has not been
reported to enhance the risk of cancer significantly [64].
On the other hand, BMPs show dose-dependent efficacy,
where lower doses were inferior with regard to amount, qual-
ity, and time required for bone formation when tested in spi-
nal fusion procedures in non-human primates [81, 82].
Similarly, in a study in human patients with open tibial frac-
tures, an rhBMP-2 dose of 6 mg showed 44% increase in cases
of nonunions requiring secondary interventions compared to
a dose of 12 mg [83]. The reduced efficacy associated with
lower BMP doses and compromised safety of the higher doses
form a dilemma for acquiring an optimal dose regimen. This
has stimulated the search for improved delivery systems that
allow for sustained and controlled release of the BMP.
Aim of this Review
This review addresses the carrier properties (e.g., material and
configuration) and in particular the stability of BMPmolecules
in the formulations, as these are all parameters that affect the
therapy outcomes of BMPs [23]. It has to be realized that a
number of concerns regarding the efficacy and safety of the
BMP-based approaches for bone formation have been report-
ed in the past decade. At the same time, it has been shown that
the efficacy and some of the reported side effects of the BMPs
can be controlled by improving their delivery [84]. The raise
of these concerns have, time-wise, coincided with exploding
scientific discoveries in the field of protein pharmaceuticals
and in particular concerning our understanding of how insta-
bility of proteins can lead to loss of efficacy and increased
immunogenicity [85–87]. Therefore, some of the reported
side effects and challenges arising from the utilization of
BMP-based therapies could be related to the protein stability
issues, as discussed in this review. Clearly, any potential hint
from the literature could lead to game-changing solutions to-
wards safer and more effective BMP-based therapies.
BMP DELIVERY SYSTEMS
The delivery system can be considered as the most important
parameter regarding the delivery of BMPs. A properly de-
signed delivery system is administered locally via surgery and
would be able to localize the BMP only at the target repair
site. Such a delivery construct would have a built-in release
system that is able to keep the local BMP concentration over
time high enough to induce osteoinduction and the systemic
concentration low enough to avoid the adverse events encoun-
tered with supraphysiological doses of the BMP [88].
Superiority in terms of bone regeneration and newly-formed
bone quality was demonstrated in a rat model with femoral
defects when controlled spatiotemporal BMP release from a
hybrid system composed of alginate hydrogel contained in a
nanofiber mesh was compared with the commonly used ab-
sorbable collagen sponge [89].
Furthermore, bone formation by using relatively low dose
rhBMP-2 (8 μg/ml) was achieved in mice with critical size
calvarial defects using a semi-synthetic PEGylated fibrinogen de-
livery system.Upon subcutaneous implantation, the hydrogel acts
as a matrix that can regulate the release of rhBMP-2 in physio-
logical doses at its implantation site [90]. Another delivery system
was constructed by allowing supramolecular nanofibers to form
gel networks within the pores of ACS. These nanofibers have an
affinity for binding BMP-2 with the help of heparin sulfate, and
thus increase the retention time at the site of administration/
implantation and allow for lower doses.With this delivery system,
bone regeneration was achieved in a rat critical-size femoral de-
fect model using BMP-2 doses (1 μg) that were one order of
magnitude lower than the previously reportedmodel’s minimum
threshold for healing (11μg) [73]. These and other studies suggest
that the in vivo spatiotemporal release kinetics of BMP in a deliv-
ery system will be affected by the choice of carrier material, the
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protein incorporation method and the type of protein-carrier
interaction, as well as by the carrier’s physical configuration [91].
For bone regeneration applications, tissue engineering
growth factors in general need to be delivered with a scaffold
for the purposes of providing mechanical support as well as a
three-dimensional (3D)matrix that allows for the release of the
payload and growth of the new tissue. Metal scaffolds made of
titanium are commonly used support scaffolds for bone repair
applications [92] as they can be processed into macroscopic
fiber meshes and porous scaffolds, and thus create a suitable
environment for tissue growth and allow for its integration
with the native bone [93, 94]. However, rhBMP molecules
incorporated into titanium support scaffolds are either
adsorbed to the surfaces or are superficially entrapped and
therefore can be rapidly released in vivo [95]. The incorpora-
tion of one or more protein carriers is thus essential for sus-
taining the rhBMP release in vivo.
The carrier material can be either formulated into a scaffold
that serves as both the required mechanical support and the
delivery system for rhBMPs, or formulated only as the delivery
system which is then incorporated into/onto a separate scaf-
fold. Examples of the latter include the formulation of rhBMP-
2 into polymeric carriers such as hyaluronic acid (HA) [96] and
polylactic acid [97] which were then coated onto the surface of
titanium scaffolds and tested in rats and sheep, respectively.
The formulation of the delivery system into different configu-
rations (e.g., solid or hydrogel scaffolds, micro- and nanoparti-
cles) and the method of the protein incorporation/
immobilization with the carrier are all factors that influence
the overall conditions of delivery and, consequently, the clinical
effects. Figure 2 demonstrates the different carrier configura-
tions and BMP immobilizations strategies.
Carrier Materials
Different types of carrier materials have been investigated for
their capability of delivering rhBMPs and assessed for their
general performance in achieving osteoinduction. Different
carrier materials have been commonly classified according
to their nature of origin and chemical composition into four
main classes: natural polymers, synthetic polymers, inorganic
materials, and their composites. Each class has advantages
and disadvantages over the others. This is why no carrier for
the delivery of BMPs is considered universally accepted, but
rather some carriers become more suitable than others with
respect to a certain application. This section contains an over-
view of the most commonly researchedmembers of each class,
their general advantages and drawbacks, and examples of the
findings regarding their use in delivery of rhBMPs (see Table I
for an overview of the carriers covered in this review). For a
Fig. 2 Illustrative diagram of BMP
immobilization approaches. (a)
rhBMP immobilization methods on
single-material scaffolds: adsorption
(left), chemical immobilization
(middle), and physical entrapment
(right). A postulated release profile is
displayed beneath each method. (b)
Examples of potential rhBMP
multiple immobilization methods
on either single-material or
composite scaffolds: combination of
adsorbed and physically
immobilized BMP (left), particle-
encapsulated BMP incorporated
into a scaffold along with BMP
directly physically immobilized into
the scaffold (middle), and additional
chemical immobilization of the BMP
onto the composite scaffold (right).
A postulated release profile is
shown below each method.
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Table I Overview of the Carriers Covered in this Review
Class Types Delivery form(s) Preclinical studies Reference
Natural polymers Collagen Powders BMP-2 in:
Membrane films - Maxillofacial reconstruction in Rhesus monkeys [104]
Aqueous forms - Rabbit ulna osteotomy model [103]
Gels - Healing in goat tibial fracture model [102]
Nanofibers BMP-7 in:
Putty - Healing of segmental defects in
non-human primates
[101]
Absorbable sponge - Lumbar vertebral interbody fusion in sheep [100]
Hyaluronic acid/Hyaluronan BMP-2 in:
Gels - Dog alveolar ridge defects [113]
Scaffolds - Mid-tibial unions in rabbits [114]
Aqueous forms - Rat calvarial defects [115]
Gelatin BMP-2 in:
Hydrogel - Ulnar bone segmental defects in New Zealand
White rabbits
[117]
Microparticles on a composite
scaffold








Film - C2C12 cell line of mouse muscle myoblast cells [121]
Alginate BMP-2 in:
Aqueous form - Posterolateral spine fusion in rabbit model [122]
Silk BMP-2 in:
Film - Cell culture inserts [126]
3-D porous scaffolds - Critical sized cranial defects in mice [125]
Microparticles - Rat ectopic model [124]
Synthetic polymers Poly-α-hydroxy acids BMP-2 in:
i) Polylactic acid (PLA) Aqueous form - Canine posterolateral spinal fusion model [128]
Preshaped implants - Mandibular bone repair in rats [127]
ii) Polyglycolic acid (PGA) BMP-2 in:
Nonwoven fabric made from
PGA fibers, scaffolds,
nanoparticles
- Induction of bone is Wistar rat thigh muscle [131]




Microparticles - Intramuscular bone induction in mice [136]
Implants - Mandibular defects in canine model [135]
3-D scaffolds - Differentiation of rabbit bone marrow stromal
cells
[134]
Capsules - Segmental bone defects in rabbit radius [133]
BMP-7 in:
Gels - Bone formation from rabbit skeletal muscle cells [132]
Polyethylene glycol (PEG) BMP-2 in:
Hydrogel - Critical-sized defects in rat crania [137]
Poly-ε-caprolactone (PCL) BMP-2 in:
3-D scaffolds - Osteoinduction in bone marrow stromal cells [140]
Polypropylene fumarate (PPF) Porous scaffolds BMP-2 in: [141]
- Goat ectopic implantation model
Poloxamers Freeze-dried powder BMP-2 in: [142]
- Bone induction in Swiss-Webster mice
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more extensive review of all the available carrier materials
studied in combination with rhBMPs, the reader is referred
to other detailed review articles [24, 84, 98, 99].
Natural polymers have been largely investigated for the delivery
of rhBMPs because of their favorable characteristics that in-
clude biocompatibility, biodegradability, and solubility in phys-
iological environments. Since most natural polymers are de-
rived from animals, they possess the disadvantages of immuno-
genicity and the potential risk of transmitting animal-originated
pathogens as well as the general difficulty in their processing.
Collagen has been the most extensively used carrier for delivery
of rhBMPs, and it is the carrier employed in both commercial
rhBMP products (INFUSE® and OP-1®). The facts that col-
lagen is the most abundant non-mineral component of bones
and that it can be easily isolated and purified enzymatically
from various animal species make it a highly favorable carrier
candidate for rhBMP. Collagen has been fabricated as powder,
membrane films, aqueous forms, gels, nanofibers, and the most
common, absorbable sponge [95, 99–104].
Despite its optimal biocompatibility, collagen possesses a
number of disadvantages. As a scaffold, collagen is mechani-
cally weak and therefore, when implanted in an environment
where the sponge is compressed by surrounding muscles and
tissue, undesirably high doses of rhBMPs could be locally re-
leased [24, 95]. Furthermore, the biodegradation of the col-
lagen matrix is unpredictable and difficult to control, resulting
in undefined release kinetics of the entrapped protein [105].
Even though the rhBMP-2 retention at the defect site was
prolonged by its incorporation into a collagen sponge when
compared to buffer only, it was shown in vivo that only 5% of
the protein remains within the collagen after 2 weeks due to
initial burst release [106, 107]. In addition, collagen possesses
immunogenic properties due to its common extraction from
bovine and porcine skin, where 20% of patients receiving
rhBMP-2/ACS were found to have developed antibodies
against type I collagen [99]. Another problem encountered
with collagen is sterilization difficulty, where heat sterilization
causes complete or partial denaturation where the collagen
Table I (continued)
Class Types Delivery form(s) Preclinical studies Reference
Block copolymers BMP-2 in:
i) PLA-PEG Pellets - New bone induction in dorsal
muscles of mice
[145–147]
ii) PLA-DX-PEG BMP-2 in:
implant - New bone induction in dorsal muscles of mice [148]
Inorganic materials
(ceramics)
Calcium Phosphate Materials BMP-2 in:
i) Hydroxyapatite Fiber mesh - Rat posterolateral spinal fusion [153]
Cement - Rabbit unilateral radii defect [154]
BMP-7 in:
Porous scaffold - Spinal fusion in sheep model [155]
- Orthotopic calvarial defects in baboons [156]
ii) β-tricalcium phosphate (TCP) BMP-2 in:
Porous multi-cylinder scaffolds - Long intercalated rib defects in dogs [160]
Cement - Trepanation defects in sheep [161]
Granules - Spinal fusion in canines [162]
iii) Biphasic calcium phosphate (BCP) BMP-2 in:
Scaffolds - Rat calvarial bone defects [164]




PEGylated fibrinogen Hydrogel BMP-2 in critical size calvarial defects in mice [90]
RGD-Alginate Nanofiber mesh hydrogel BMP-2 in bilateral critical size defects in rats [166]
PCL-Collagen Nanofibrous scaffold BMP-2 in in vitro activation of pre-osteoblasts [167]
CMC-Collagen Putty BMP-7 in critical size defects in ovine tibiae [168]
Polymers + Ceramics
Collagen-Biphasic calcium phosphate




Hydrogel BMP-2 in cranial defects in rabbits [174]
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helices become irreversibly damaged [106, 108]. Thus, usual-
ly ethylene oxide is used to sterilize the collagen sponge.
However, this method of sterilization poses the risk of affecting
the rhBMP’s release kinetics and structural integrity, and con-
sequently its bioactivity [109], as was demonstrated by the
reduced bone-inducing capacity of the extracted BMP after
exposure to ethylene oxide [110–112].
Hyaluronic acid (HA), also called hyaluronan, is another
natural polymer which has been studied for delivery of
rhBMPs. Successful bone regeneration was reported with
the use of HA as a carrier for rhBMP-2 in dog alveolar ridge
defects [113], mid-tibial non-unions in rabbits [114], and rat
calvarial defects when surgically administered in combination
with mesenchymal stem cells [115]. When compared with a
composite carrier made of collagen, hydroxyapatite and
tricalcium phosphate, HA based delivery of rhBMP-2 pro-
duced larger bone and osteoid volumes [116].
Gelatin, which is denatured collagen, is another promising
carrier for rhBMP-2. rhBMP-2 formulated in a macroscopic
gelatin hydrogel was shown to be capable of inducing
osteoinduction in ulnar bone segemental defects in skeletally ma-
tureNewZealandWhite rabbits [117]. Similarly, rhBMP-loaded
gelatin microparticles in a poly propylene fumarate scaffold
showed controlled and sustained release in amousemodel [118].
Fibrin, derived from blood clots, has also been used as a
carrier for rhBMP-2 and the construct has significantly in-
creased the formation of bone in calvarial bone defects in
New Zealand White rabbits [119]. Fibrin along with HA
and type 1 collagen in combination with heparin and
rhBMP-2 demonstrated complete bone healing in a cranial
implant model [120]. Other natural polymers that were stud-
ied as carriers for rhBMP include chitosan (a cationic copoly-
mer prepared from chitin) [121], alginate (a polysaccharide
obtained from sea weed) [122], and silk [123–126].
Owing to their flexible and easily controlled design, biode-
gradable synthetic polymers have been investigated as carriers for
rhBMPs in bone tissue engineering applications. Poly-α-
hydroxy acids are commonly used synthetic polymers in growth
factor delivery; and their capacity for delivering rhBMP has
been investigated [24]. rhBMP-2 successfully induced bone
formation in various animal models when delivered by a ma-
trices of polylactic acid (PLA) [127, 128], polyglycolic acid
(PGA) [129–131], and their copolymer poly(D,L-lactide-co-
glycolide) (PLGA) [132–136]. Other synthetic polymers that
have been studied in combination with BMPs include poly-
ethylene glycol (PEG) [137], polyanhydrides [138, 139],
poly-ε-caprolactone (PCL) [140], polypropylene fumarate
(PPF) [141], and poloxamers [142]. General advantages of
this group of materials include their biocompatibility, hydro-
lytic biodegradability, low immunogenicity risk and eliminat-
ed possibility of disease transmission in addition to their gen-
eral ease of use, formability and design flexibility
[98, 143, 144]. An additional advantage of these materials
over natural polymers is their ability to tailor the mechanical
strength, adhesiveness and degradability according to their
clinical use requirements through manipulating the polymer
structure [98]. An approach that is often followed is the syn-
thesis of block copolymers by polymerizing chains of different
blocks in an attempt to control/manipulate one ormore of the
polymeric delivery system’s characteristics, such as its release
kinetics. An example is the incorporation of rhBMP-2 in a
delivery system based on PLA-PEG copolymer that is im-
planted in the form of a viscous liquid or pellets [145–147].
Even though PLA-PEG proved to be useful as a matrix for
osteoinductive rhBMP-2, it was found that its degradation was
too slow and that some of the carrier material remained at the
center of the formed ossicles. Keeping the polymer molecular
weight constant, para-dioxanone molecules were randomly
inserted into the PLA segments of the PLA-PEG polymer
creating the polymer PLA-DX-PEG. This modification aided
in optimizing the degradation kinetics of the polymer. Using it
as a delivery system for rhBMP-2 resulted in complete re-
placement of the implants by new bone without detectable
polymer remnants inside the formed ossicles [148]. Many of
the synthetic polymers, however, have the disadvantage of
acidic breakdown byproducts that lower the local pH and
potentially increase the associated risk of excessive inflamma-
tory responses. Moreover, this acidification as well as the hy-
drophobic character of polymers like PLGAmay compromise
the protein stability [149]. Retarded clearance rate, lack of
biological function, and chronic inflammation associated with
high molecular weight polymers are other drawbacks encoun-
tered with the use of some synthetic polymers [95, 98, 99].
Inorganic materials (mainly ceramics) are another class of car-
rier materials that are investigated for delivery of rhBMPs.
Calcium phosphate materials are the most common inorganic
materials used in bone tissue regeneration because of their
established ability for osteoconduction [150–152]. According
to their chemical composition, the most used calcium phos-
phates are subdivided into three main categories: hydroxyap-
atite, β-tricalcium phosphate, and a combination of both
called biphasic calcium phosphate [24]. Administration of
rhBMP incorporated into a hydroxyapatite carrier demon-
strated bone formation with rhBMP-2 in rat posterolateral
spinal fusion [153] and rabbit unilateral radii defect [154].
The same carrier has also been used for rhBMP-7 in spinal
fusion in a sheep model [155] and in baboon orthotopic
calvarial defects [156]. In contrast, rhBMP-2 delivered with
hydroxyapatite failed to demonstrate any capability of bone
formation after subcutaneous implantation in rats [157],
which was later reasoned to be due to high affinity between
the carrier material and the protein [99].
Disadvantages associated with hydroxyapatite are related to
its brittleness, poor resorbability, and insufficient mechanical
strength [24]. A comparison held by Tazaki et al. between hy-
droxyapatite and β-tricalcium phosphate revealed the superiority
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of the latter owing to its relatively slower rhBMP-2 release rate
[158]. For this reason and in addition to its chemical similarity to
the normal bone structure, β-tricalcium phosphate has been the
most commonly used bone graft substitute [150]. Furthermore,
its biocompatibility, degradability, and low immunological and
toxic reactions make it a potentially promising carrier for BMPs
in bone tissue engineering [95, 159]. rhBMP-2 delivered by β-
tricalcium phosphate in the form of solid cylinders was able to
repair long intercalated rib defects in dogs [160], fill trepanation
defects in sheep [161], and achieve posterolateral lumbar
interbody fusion in dogs [162].
Biphasic calcium phosphate has been investigated to employ
the different resorbability characteristics of hydroxyapatite and
β-tricalcium phosphate to control the degradation kinetics by
varying between their ratios [163]. Biphasic calcium phos-
phate, formed of hydroxyapatite and β-tricalcium phosphate
in different ratios, demonstrated enhanced bone formation in
a rat calvarial defect model [164] and in non-human primate
intertransverse process spine arthrodesis [82]. Phase separation
in case of administration by injection, lack of intrinsic
macroporosity to allow cell infiltration and low mechanical
tensile and shear properties compared to bone and other ma-
terials are all among the main disadvantages of calcium phos-
phate materials [98]. However, some of the problems could be
resolved through formulation modifications, such as increasing
macroporosity by the addition of gas producing excipients to
induce granulation or to form pores [165].
In recent years, the trend has shifted towards delivering
rhBMP using Composite carriers of different origins instead of
a single carrier material. Such an approach would allow the
designer to combine the benefits of the multiple materials to
optimize the properties and to overcome some of the encoun-
tered limitations. The fabrication of semi-synthetic polymers
was introduced to combine the controlled release advantages
of synthetic polymers with the biocompatibility of natural
polymers. These semi-synthetic polymers were successful in
delivering rhBMPs and promoting osteoinduction in many
studies. Recent examples include the use of PEGylated fibrin-
ogen with low dose rhBMP-2 in critical size calvarial defects in
mice [90], RGD-alginate hydrogel containing rhBMP-2 in
bilateral critically-sized femoral bone defects in rats [166],
and poly-ε-caprolactone (PCL) combined with collagen and
low dose rhBMP-2 in in vitroMC3T3-E1 cells (pre-osteoblasts)
[167]. As for delivering rhBMP-7, a putty composed of a
combination of carboxymethyl cellulose (CMC) and collagen
was investigated for its effectiveness for osteoinduction in crit-
ical size defects in ovine tibiae [168], and in spinal fusion
procedures in ovariectomized female (osteoporotic) rats [169].
Composites with the addition of polymers (natural or
synthetic) to ceramics have been synthesized with the pur-
pose of improving the handling, porosity, and in some
cases injectability of the ceramic carriers [170–172]. As
a recent example, a disk-shaped, solid composite of
collagen and biphasic calcium phosphate was prepared
for rhBMP-2 delivery in rabbit calvarial defects and
showed superiority over collagen-free biphasic calcium
phosphate in terms of decreased burst release and bone
regeneration [173]. More complex three-component com-
posites were also synthesized for the purpose of bone re-
generation, as demonstrated by the achieved injectability
and thermo-sensitivity of the novel hydrogel PEG-PCL-
PEG copolymer/collagen/n-hydroxyapatite [174].
Carrier Configurations and Protein Incorporation
The simplest forms of carrier configurations are micro- or
nanoparticles acting as simple depot delivery systems for the
BMPs without contribution to the mechanical support func-
tions. Besides, these delivery systems are generally considered
cheap, simple, and efficient vehicles for drug delivery and/or
targeting [84]. An early study tested the delivery of PLA mi-
croparticles for delivery of BMPs for bone formation in rats
[175]. However, PLGA has caught the focus owing to its
relatively controllable biodegradability by changing its PLA
and PGA ratios [84, 176], and has thus beenmore thoroughly
investigated for the delivery of rhBMPs in the forms of parti-
cles with a wide range of sizes from 430-μm microparticles
[177] down to 300-nm nanoparticles [178]. To maintain the
particles at the defect site for the essential local release of the
incorporated BMP, they need to be retained within a scaffold.
PLGA microparticles containing rhBMP-2 have commonly
been incorporated in calcium phosphate cement scaffolds,
which further prolong the release, an effect which has been
attributed to possible affinity between rhBMP-2 and the scaf-
fold [178–180]. Wei et al. encapsulated rhBMP-7 in PLGA
nanospheres that were incorporated into a PLA scaffold. It
was concluded that the carrier was able to deliver rhBMP-7
in a time-controlled manner and was able to significantly in-
duce bone formation in a rat model [181].
Natural polymers were used to create BMP-containing
microparticles as well. Osteoinduction was promoted upon
rhBMP-2 delivery via nanoparticles made of dextran in
rabbit bone marrow stem cells, and via microparticles
made of the composites chitosan-alginate and dextran-
gelatin [182] in rabbit bone marrow stem cells and in vivo
in canine defects, respectively. It is well established that the
use of particulate delivery systems such as micro- and
nanoparticles bears an immunogenicity risk, as they are
readily taken up in vivo by dendritic cells and macrophages
initiating an immune response against the delivered pro-
tein/peptide. This risk, when added to the immunogenic
nature of BMPs [183], could be detrimental for the thera-
py. Therefore, it would be wise to investigate the effect of
delivering rhBMPs via this type of delivery systems on the
expression of antibodies against the protein [85, 184].
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Carriers have also been fabricated into macroscopic
hydrogels and porous solid scaffolds that may contribute to the
requiredmechanical support for 3D cell growth beside their role
in delivering BMPs. Examples of the use of natural polymer
scaffolds include all the animal and clinical studies utilizing
rhBMP-2 soaked into collagen sponge (ACS) scaffolds as well
as rhBMP-2 formulated into porous HA scaffolds [185]. BMPs
have also been delivered by using composite solid scaffolds, e.g.,
chitosan-PGA [186], gelatin-β-tricalcium phosphate [187], and
PLA-PEG-calcium hydroxyapatite [188]. Hydrogel scaffolds of-
fer another configuration for the carrier materials used for de-
livery of BMPs. Unlike solid scaffolds, hydrogels are fabricated
to contain a large amount of water and are characterized by
swelling through increasing the water content upon implanta-
tion in vivo. This highly hydrated state allows for the free diffusion
of oxygen and nutrients into the scaffold, and thus provides an
optimum environment for the new bone tissue ingrowth
[189–193]. Hydrogels are synthesized by crosslinking the
branches of hydrophilic polymers using a bridging agent; where
the water content depends on the type and concentration of the
molecules and the bridging agent [95]. Examples of incorpora-
tion of BMPs within hydrogel scaffolds include the inclusion of
rhBMP-2 into gelatin hydrogels with different water contents
[117, 194], and rhBMP-2 alongwith humanmesenchymal stem
cells incorporated into a HA hydrogel administered for rat
calvarial defect regeneration [115]. Another type of scaffolds
composed of 3D nanofiber structure prepared by using an
electrospinning technique. This type of structure provides a high
surface area-to-volume ratio, thus enabling the adhesion and
proliferation of osteogenic cells. Electrospun scaffolds prepared
from chitosan [195], silk [196], and PCL-PEG [197] are select-
ed examples investigated for their ability to deliver rhBMP-2.
The release pattern of the bone morphogenetic protein
depends greatly on the type of interaction between the protein
molecules and the carrier and generally the way the molecules
are incorporated into the delivery system (Fig. 2). Physical
adsorption to the delivery system’s surface is considered the
simplest form to deliver the protein where the prefabricated
scaffold is dipped into the protein solution and left to dry, in
which there is no specific affinity between the protein and
carrier molecules. The main disadvantage of this interaction
is that the adsorption and dryingmay result in alteration of the
conformational structure of the protein molecules with the
possibility of affecting its bioactivity [91]. Physical entrapment
of the protein within the delivery system material is another
way of protein incorporation. This technique usually takes
place by mixing the BMPs with the carrier material in its
liquid form followed by phase change, such as gelation, lead-
ing to entrapment of the protein molecules. In a slightly dif-
ferent format, usually utilized with natural polymer sponges
and hydrogels, the carrier is soaked in the protein solution just
prior to implantation (the method used in commercially avail-
able product INFUSE®), allowing the protein to be loaded
into the pores of the carrier material. When such a delivery
system is subjected to the in vivo physiological environment,
however, the protein may be released in a rapid uncontrolled
fashion by diffusion through the delivery system and/or by
degradation of the carrier material.
Covalent coupling of BMPs to the carrier material is a way
to circumvent the limitations of surface adsorption and phys-
ical entrapment techniques for a more stable and sustained
release. The immobilization depends on the presence of es-
sential functional groups both on the protein and carrier mol-
ecules that would allow for the formation of a suitable covalent
bond through bifunctional crosslinking or derivatizing re-
agents. One major drawback associated with the covalent
bonding is that the drug substance is chemically altered, which
may result in alteration in activity and interaction of the mol-
ecule with its environment.Modification of the drug substance
may also lead to complications with respect to regulatory ap-
provals of the product. Additionally, concerns have been
raised regarding the effect of chemical coupling on changes
in proteins structure and bioactivity and safety in general
[198], and BMP-2 in particular [199]. Furthermore, the co-
valent bonding restricts free diffusion of the protein molecules
within its microenvironment which might hamper the inter-
action with the appropriate receptors for osteoinduction.
Encapsulation of BMPs into micro- and nanoparticles may
bypass most of the aforementioned issues regarding rapid re-
lease, however, many of the encapsulation techniques involve
harsh conditions, such as the use of organic solvents, exposure
to interfaces and acidic environment, all of which may subject
the protein molecules to physical and/or chemical instability
resulting in diminished bioactivity among other complications
[24, 200, 201].
STABILITY OF BMPS
Proteins existing in their native state usually express low sta-
bility. Even minor changes in their surrounding environments
can account as stress for the proteins, which may lead to
chemical changes (e.g., oxidation and deamidation), physical
changes (e.g., unfolding or misfolding, aggregation and parti-
cle formation), and surface adsorption, processes which may
mutually influence each other. For instance, surface adsorp-
tion can potentially lead to changes in a protein’s structural
integrity or aggregation, and conformational changes may
trigger chemical degradation reactions [202]. Protein degra-
dation can easily occur during the different processes that the
protein needs to undergo until it reaches the patient, e.g.,
during production, storage, and administration. During such
processes, the protein in its surrounding environment is sub-
jected to several stress factors, such as elevated temperature,
undesirable solution pH, presence of co-solutes in the aqueous
solution such as salts, preservatives and surfactants, and
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contact with handling tools and other components of the for-
mulation and delivery systems [203].
Despite its importance in efficacy and safety of the treat-
ment, the subject of rhBMP stability and the factors affecting it
has been addressed in only a handful of the published studies.
Even fewer publications discussed the impact of such protein
stability/instability on the in vivo activity and adverse effects.
BMPs, like proteins in general, adopt a unique 3D structure in
their aqueous environment that is essential for their bioactiv-
ity. Any alteration to this native protein conformation can lead
to partial or total inactivation of the protein. Chemical and
physical instability may lead to reduced or diminished activity
and adverse effects, such as immunogenicity [87, 204, 205].
The presence of particulates may also lead to several side
effects, such as local phlebitis, pain, swelling, inflammation,
granuloma, anaphylactic or allergic reactions [86].
Although antibodies against administered rhBMP-2 and
rhBMP-7 [35, 62, 70] and accompanying immediate pain
[41, 206] have been reported following rhBMP-2 treatments,
the possible relationship between the potential presence of sol-
uble aggregates and/or particulates in BMP formulations and
the observed adverse effects have, to our knowledge, not been
studied. Furthermore, stability studies have, in most cases, not
been reported on the rhBMP-7 formulation to determine
whether or not the resultant inadequate efficacy was due to
decreased bioactivity through denatured protein [70].
Similarly important and greatly neglected is the potential effect
of protein degradation on the efficacy of BMP proteins. For
instance, destabilized disulfide bonds, which commonly occur
in neutral and basic environments, may result in their breakage
and thus disruption of the dimeric nature and inactivation of
BMPs [207]. Despite the fact that several studies state that a
large amount of BMP was needed to get a biological response,
little has been done to investigate whether the administered
protein is still in its native form and active. Clearly, denatur-
ation and subsequent inactivation could at least partially ex-
plain the need for BMP amounts up to a million-fold higher
than biological concentrations for a successful effect.
A few limited studies have been published about the effect
of elevated temperature (one of the stress factors BMPs com-
monly encounter during their production and formulation) on
BMP stability. Crude human BMP was extracted from bone
that was subjected to 60°C for 10 h and compared to the
protein extracted from non-treated bone by sodium dodecyl
sulfate polyacrylamide gel electrophoresis. The electrophoret-
ic bands were found to be identical for the BMP from both
bone sources, suggesting that the primary structure of the
protein was not altered. Similar bone formation was also ob-
served after implantation of the differently treated BMPs into
thigh muscle pouches of five mice [208]. In another study, the
bone-inducing activity of rhBMP-2 samples was determined
before and after heating at different temperatures (50, 70, 90,
100, and 120°C) for different time periods (15 min, 1, 2, 4,
and 8 h). The in vitro testing was done by adding the rhBMP-2
samples to cell cultures of MC3T3-E1 cells and testing the
alkaline phosphatase activity (an early biomarker of osteoblas-
tic differentiation and its expression is induced by BMP in a
dose-dependent manner [209]) after 48 h. The rhBMP-2
bone-inducing activity was also tested in vivo by implanting
freeze-dried collagen disks containing the rhBMP-2 samples
into mice back muscles and examining the new bone forma-
tion into the disks after three weeks using radiography. The
results of this study suggested that the rhBMP-2 is resistant to
incubation at 50 and 70°C for short periods, while degrada-
tion starts at higher temperatures and/or long periods where
heating at 120°C completely inactivated the protein [210].
The activity of BMP-7 extracted from human femoral bone
headwas tested in another study after exposure to both high and
low temperatures. The aim of the study was to investigate the
resistance of BMP-7 in tumor-bearing bones against freezing,
pasteurization, and autoclaving treatments applied during bio-
mechanical reconstruction procedures after bone tumor resec-
tion. The BMP-7 was subjected to −196, −73, 60, and 100°C
for different time periods (20, 30min, 10, and 12 h). The treated
samples were analyzed in vitro for their BMP-7 content by using
enzyme-linked immunosorbent assay (ELISA). A bioassay was
also performed using NIH3T3 mouse fibrous cells and immu-
noblotting analysis to detect the amount of phospho-Smad,
which is an indicator of the BMP-7 activity. The results showed
that the BMP-7 retains its activity after freezing (−196 and
−73°C) and thawing, while it partially loses it upon incubation
at elevated temperatures (60 and 100°C) [211].
There are some points to note concerning the studies on
the thermal stability of BMPs. Firstly, two of the studies are
relatively old (2001 and 2005, respectively) and used only a
few methods to study the protein’s stability in vitro. This fact
would certainly compromise the significance of these results to
the accurate physical stability information required nowadays
[85, 212, 213]. Secondly, the studies by Izawa et al. and
Takata et al. have used BMPs that were extracted from human
bone rather than recombinant proteins, which again compro-
mises the relevance of their results to the behavior of the
marketed recombinant proteins to stress. Furthermore, these
studies were focused on BMP activity and bone formation and
did not study the actual effects of the temperature on the
native structure and aggregation of the protein and therewith
potential signs of adverse effects and toxicity/immunogenicity.
The pH of the solution environment is another important
parameter that can greatly affect the rhBMP stability. The
type and number of the charges carried by a protein is affected
by the pH of its surrounding aqueous environment. These
charges affect the electrostatic interactions among the differ-
ent amino acids in the same protein molecule as well as inter-
molecular and molecule-environment interactions. Protein
molecules have a neutral net charge at pH values close to their
isoelectric points, while they carry positive or negative charges
Formulation, Delivery & Stability of Bone Morphogenetic Proteins
in more acidic or basic conditions, respectively. The stability is
unsurprisingly dependent on the balance between attractive/
repulsive interactions among the present charges. Exposure of
a protein to a pH environment that is far from its isoelectric
point, results in strong repulsive forces between its charged
groups. Consequently, unfolding may become thermodynam-
ically favorable in this state, as the charge density on the folded
protein is higher than on the unfolded protein. In contrast,
having a neutral charge reduces the electrostatic repulsion,
where hydrophobic attraction between the protein molecules
becomes dominant, which could possibly lead to aggregation.
Furthermore, specific electrostatic attraction can arise be-
tween the charged groups and the oppositely charged ions in
the surrounding environment forming salt bridges. This form
of interaction has been reported to promote the conforma-
tional stability of the protein by stabilizing the folded state in
some cases [203].
Of all the BMPs, we were only able to gather pH-
dependent stability information for rhBMP-2. The charge dis-
tribution of rhBMP-2 is displayed in Fig. 1 [18] and its iso-
electric point is 8.2 [23]. Early reports showed loss of rhBMP-
2 solubility at pH values above 6 [214, 215], which is probably
a part of the reason that the marketed product INFUSE® is
formulated at a relatively low pH of 4.5 [216]. A study was
conducted to investigate the effect of the formulation pH (4.5
versus 6.5) on the conformational stability and aggregation
state of rhBMP-2. The analysis was done by using modern
complimentary analytical techniques such as intrinsic and ex-
trinsic fluorescence spectroscopy, light scattering, and trans-
mission electron microscopy that look at the 3D structure of
the protein as well as its state of aggregation. The results con-
firmed the loss of solubility at the higher pH as previously
reported and indicated the presence of larger size and higher
amounts of aggregates accompanied by conformational
changes in the higher pH formulation. This was explained
by the increased contribution of the hydrophobic attractive
interactions by increasing the pH closer to the pI value [23].
The abundance of the surface hydrophobic regions (seen in
white in Fig. 1) supports the proposed explanation. It is note-
worthy that smaller aggregates (100 nm) were present in the
formulation with pH 4.5 as well. This could be an indication
of the need for reformulation of this product.
The incorporation of a protein into a delivery system im-
plies changes in the immediate environment of the protein
molecules and can alter the type and extent of interactions
that may increase or decrease their physical stability. This
was demonstrated when the pH of the rhBMP-2 formulation
shifted from pH 4.5 to higher pH upon its addition to the
collagen sponge [216–218]. Luca et al. evaluated the effect of
the carrier nature and pH on the in vivo osteoinduction of
rhBMP-2 in quadriceps muscles of Sprague-Dawley rats.
The reconstructed rhBMP-2 solution at pH 4.5 was mixed
with either chitosan or HA at two pH values (4.8 and 6.2)
for each carrier to form injectable hydrogels. Chitosan and
HA are two polymers with similar chemical structures but
carrying opposite charges. This means each of them will in-
teract differently when mixed with the positively charged
rhBMP-2. Electrostatic attraction would dominate between
the negatively charged HA and rhBMP-2, while hydrophobic
attraction and hydrogen bonding would govern the interac-
tion between the positively charged chitosan and rhBMP-2.
This difference in the interaction types would probably result
in different release patterns and possibly different protein sta-
bility. rhBMP-2 delivered via both hydrogels was shown to
promote bone formation effectively. rhBMP-2 when delivered
with HA induced the production of bone with significantly
higher level of mineralization, while when delivered with chi-
tosan it resulted in more mature bone. These results indicate
that the carrier type indeed has an effect on the quality of the
formed bone. Confirming the previously reported pH effect,
rhBMP-2 in lower-pH hydrogels (4.8) formed higher miner-
alized bone compared to the higher-pH hydrogels (6.2) [219],
which could be an indication of potential contribution of BMP
stability to the observed effect.
In a recent study, a novel composite carrier was developed
that was composed of polycaprolactone and type-1 collagen
and osteoprogenitor cells and was formulated into a scaffold.
However, 2-fold loss in rhBMP-2 bioactivity was reported
after mixing with the developed carrier. The addition of hep-
arin and/or bovine serum albumin to rhBMP-2 before its
incorporation into the scaffold helped to preserve its bioactiv-
ity [220]. This observation is in line with the notion that the
choice of carrier type may influence the physical interaction
between the protein and carrier material, and thereby the
structure and bioactivity of the protein.
There are other causes of protein instability that are only
briefly addressed for rhBMPs among the published body of
literature. The presence of additives and cosolutes can either
physically stabilize or destabilize rhBMPs in aqueous solution
according to their type and concentration [203]. The
INFUSE® formulation is a lyophilized product containing
(after reconstitution) 1.5 mg/ml rhBMP-2 in 5 mM glutamic
acid buffer, 2.5% (w/v) glycine, 5 mM NaCl, 0.5% sucrose,
and 0.01% (w/v) polysorbate 80 [218]. Although formulation
developers must have tested other variants and have reasons
for choosing this composition, unfortunately, no published
information was found about the effects of the additives on
protein stability. One study reported that the stability of
rhBMP-2 obtained from the marketed product InductOs®
(BMP-P) was superior to that from R&D systems (BMP-R)
[220]. The BMP-P was reconstituted in sterile water while
BMP-R was reconstituted in 4 mM HCl to a final pH of 0.
Such extreme acidic conditions likely lead to destruction of the
protein prior to any analysis. Shear stress applied to the for-
mulation during transport, reconstruction, and administration
(e.g., by injection) has also been mentioned as an important
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factor to be investigated for its effects on the structural integ-
rity of BMPs [221], although later studies suggested that these
effects are likely due to exposure to interfaces rather than
shear stress [222, 223].
CONCLUDING REMARKS
Bone morphogenetic proteins present a promising therapy for
critical bone defects owing to their excellent capabilities for
osteoinduction. However, like other growth factors, their de-
livery needs to be optimized in terms of the administered dose
and their localization at the defect site to improve their effica-
cy and reduce side effects associated with their pleiotropic
actions upon their presence in the systemic circulation.
Many of the side effects reported with the use of commercial
BMP products (INFUSE® andOP-1) have been connected to
their supra-physiological administered dose. Therefore, dur-
ing the recent years, research has been focusing on the devel-
opment of carriers with improved release kinetics in order to
localize and deliver lower BMP doses.
The side effects reported in clinical trials could well be
linked to the properties of the formulation and delivery meth-
od as well as the associated instability of BMP, however, these
aspects have been mainly overlooked in the published litera-
ture. For instance, the current knowledge indicates that the
shortage of efficacy and formation of ectopic bone as well as
inflammation and prolonged pain can well be related to the
non-optimal delivery method and protein instability. Despite
the fact that some studies have shown a significant level of
success concerning bone formation with lower doses of BMP
just by optimization of the formulation and delivery method,
the field seldom addresses the potential relation of the carrier
type and formulation conditions with preservation of the na-
tive structure of the BMP.
Similarly, although the field has been successful in produc-
ing several complex composite carriers that were able to clin-
ically induce bone formation, there is a lack of comparative
studies differentiating between the types of carriers and their
subsequent effect on the formed bone quantity and quality. In
fact, the approaches towards the in vitro and in vivo studies in
this area have not significantly changed since the advent of the
first BMP product, whereas the understanding of the relation
between protein structure and its efficacy and safety as well as
formulation effects has been revolutionized in the past decade.
Furthermore, enormous progress has been made in invention
and employment of novel methods that allow for characteri-
zation of proteinaceous growth factors such as BMPs with
respect to their primary, secondary, tertiary and quaternary
structures as well as their interactions with their environment.
Overall, there is a need for new studies investigating the
stability of rhBMPs addressing the current delivery ap-
proaches and using complementary analytical techniques to
monitor chemical and conformational changes as well as ag-
gregation, e.g., through forced degradation studies [224]. It
would be very rewarding to address these points in future
studies to understand the relation between formulation and
delivery with the protein structure, activity, retention and re-
lease and with bone formation quantity and quality. Taking
these considerations in future research would provide valuable
information that can be used to further enhance the delivery
conditions of BMPs, thus enhancing their efficacy and reduc-
ing their side effects.
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